Serum soluble CD26 levels: Diagnostic efficiency for atopic dermatitis, cutaneous T-cell lymphoma and psoriasis in combination with serum thymus and activation-regulated chemokine levels

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 1, 2013, Pages 19-24

  Miyagaki, T ^a   Sugaya, M ^a   Suga, H ^a   Morimura, S ^a   Kamata, M ^a   Ohmatsu, H ^a   Fujita, H ^a   Asano, Y ^a   Tada, Y ^a   Kadono, T ^a   Sato, S ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ADULT; ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DIAGNOSTIC VALUE; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; SENSITIVITY AND SPECIFICITY;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHEMOKINE CCL17; DERMATITIS, ATOPIC; DIPEPTIDYL PEPTIDASE 4; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; PSORIASIS; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SOLUBILITY;

EID: 84872837662     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04340.x     Document Type: Article

References (47)

1. DeMeester I, Korom S, Van Damme J, Scharpé S,. CD26, let it cut or cut it down. Immunol Today 1999; 20: 367-375.
2. Hartel S, Gossrau R, Hanski C, Reutter W,. Dipeptidyl peptidase (DPP) IV in rat organs. Comparison of immunohistochemistry and activity histochemistry. Histochemistry 1988; 89: 151-161.
3. Fox DA, Hussey RE, Fitzgerald KA, et al. Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. J Immunol 1984; 133: 1250-1256.
4. Hegen M, Niedobitek G, Klein CE, et al. The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. J Immunol 1990; 144: 2908-2914.
5. Yamabe T, Takakura K, Sugie K, et al. Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15. Immunology 1997; 91: 151-158.
6. Lambeir AM, Durinx C, Scharpé S, De Meester I,. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40: 209-294.
7. Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101: 746-754.
8. Kameoka J, Tanaka T, Nojima Y, et al. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 1993; 261: 466-469.
9. Boonacker E, Van Noorden CJ,. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003; 82: 53-73.
10. Cordero OJ, Salgado FJ, Nogueira M,. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother 2009; 58: 1723-1747.
11. Dang NH, Torimoto Y, Sugita K, et al. Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation. J Immunol 1990; 145: 3963-3971.
12. Dong RP, Tachibana K, Hegen M, et al. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation. J Immunol 1997; 159: 6070-6076.
13. Ishii T, Ohnuma K, Murakami A, et al. CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc Natl Acad Sci USA 2001; 98: 12138-12143.
14. Ohnuma K, Dang NH, Morimoto C,. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol 2008; 29: 295-301.
15. van Lingen RG, van de Kerkhof PC, de Jong EM, et al. Reduced CD26bright expression of peripheral blood CD8+ T-cell subsets in psoriatic patients. Exp Dermatol 2008; 17: 343-348.
16. Scala E, Russo G, Cadoni S, et al. Skewed expression of activation, differentiation and homing-related antigens in circulating cells from patients with cutaneous T cell lymphoma associated with CD7-T helper lymphocytes expansion. J Invest Dermatol 1999; 113: 622-627.
17. Bernengo MG, Novelli M, Quaglino P, et al. The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells. Br J Dermatol 2001; 144: 125-135.
18. Narducci MG, Scala E, Bresin A, et al. Skin homing of Sézary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood 2006; 107: 1108-1115.
19. Novelli M, Savoia P, Fierro MT, et al. Keratinocytes express dipeptidyl-peptidase IV (CD26) in benign and malignant skin diseases. Br J Dermatol 1996; 134: 1052-1056.
20. van Lingen RG, van de Kerkhof PC, Seyger MM, et al. CD26/dipeptidyl- peptidase IV in psoriatic skin: upregulation and topographical changes. Br J Dermatol 2008; 158: 1264-1272.
21. van Lingen RG, Poll MK, Seyger MM, et al. Distribution of dipeptidyl-peptidase IV on keratinocytes in the margin zone of a psoriatic lesion: a comparison with hyperproliferation and aberrant differentiation markers. Arch Dermatol Res 2008; 300: 561-567.
22. Gorrell MD, Gysbers V, McCaughan GW,. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001; 54: 249-264.
23. Kobayashi H, Hosono O, Mimori T, et al. Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus. J Rheumatol 2002; 29: 1858-1866.
24. Hosono O, Homma T, Kobayashi H, et al. Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals. Clin Immunol 1999; 91: 283-295.
25. Ajdary S, Riazi-Rad F, Jafari-Shakib R, Mohebbali M,. Soluble CD26/CD30 levels in visceral leishmaniasis: markers of disease activity. Clin Exp Immunol 2006; 145: 44-47.
26. Jafari-Shakib R, Shokrgozar MA, Nassiri-Kashani M, et al. Plasma sCD26 and sCD30 levels in cutaneous leishmaniasis. Acta Trop 2009; 109: 61-63.
27. Cuchacovich M, Gatica H, Pizzo SV, Gonzalez-Gronow M,. Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases. Clin Exp Rheumatol 2001; 19: 673-680.
28. Cordero OJ, Salgado FJ, Mera-Varela A, Nogueira M,. Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. Rheumatol Int 2001; 21: 69-74.
29. Schönermarck U, Csernok E, Trabandt A, et al. Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides. Clin Exp Rheumatol 2000; 18: 457-463.
30. Tamaki Z, Kubo M, Yazawa N, et al. Serum levels of soluble CD26 in patients with scleroderma. J Dermatol Sci 2008; 52: 67-69.
31. Kakinuma T, Nakamura K, Wakugawa M, et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001; 107: 535-541.
32. Kakinuma T, Sugaya M, Nakamura K, et al. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol 2003; 48: 23-30.
33. Hanifin JM, Rajka G,. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980; 92 (Suppl.): 44-47.
34. Rajka G, Langeland T,. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1989; 144: 13-14.
35. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
36. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, 4th edn. IARC Press, Lyon, 2008.
37. Miyagaki T, Sugaya M, Fujita H, et al. Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma. J Invest Dermatol 2010; 130: 2304-2311.
38. Kagami S, Sugaya M, Minatani Y, et al. Elevated serum CTACK/CCL27 levels in CTCL. J Invest Dermatol 2006; 126: 1189-1191.
39. Iwaki-Egawa S, Watanabe Y, Kikuya Y, Fujimoto Y,. Dipeptidyl peptidase IV from human serum: purification, characterization, and N-terminal amino acid sequence. J Biochem 1998; 124: 428-433.
40. Andrieu T, Thibault V, Malet I, et al. Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections. J Clin Virol 2003; 27: 59-68.
41. Kasahara Y, Fujii N, Mizukoshi M, et al. Multiple forms of glycylprolyl dipeptidyl-aminopeptidase in serum and tissues. Jpn J Clin Chem 1983; 12: 89-93.
42. Smith RE, Talhouk JW, Brown EE, Edgar SE,. The significance of hypersialylation of dipeptidyl peptidase IV (CD26) in the inhibition of its activity by Tat and other cationic peptides. CD26: a subverted adhesion molecule for HIV peptide binding. AIDS Res Hum Retroviruses 1988; 14: 851-868.
43. Zanussi S, Simonelli C, Bortolin MT, et al. Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2. Clin Exp Immunol 1999; 116: 486-492.
44. Keane NM, Price P, Lee S, et al. An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy. Clin Exp Immunol 2001; 126: 111-116.
45. Struyf S, Proost P, Schols D, et al. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol 1999; 162: 4903-4909.
46. Forssmann U, Stoetzer C, Stephan M, et al. Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo. J Immunol 2008; 181: 1120-1127.
47. Zackheim HS, Koo J, LeBoit PE, et al. Psoriasiform mycosis fungoides with fatal outcome after treatment with cyclosporine. J Am Acad Dermatol 2002; 47: 155-157.